Short answer · Medically reviewed summary · Last updated: 2026-04-08
Lysosomal acid lipase deficiency (LAL-D) is a rare metabolic disorder primarily known by two historical clinical presentations: Wolman disease (the severe early-onset form) and cholesteryl ester storage disease (CESD, the milder late-onset form). While these historical names remain common in literature, Lysosomal acid lipase deficiency is now the preferred clinical term to describe the spectrum of the disease caused by mutations in the LIPA gene. Why does Lysosomal acid lipase deficiency have multiple names? The nomenclature for Lysosomal acid lipase deficiency reflects the evolution of medical understanding.
Lysosomal acid lipase deficiency (LAL-D) is a rare metabolic disorder primarily known by two historical clinical presentations: Wolman disease (the severe early-onset form) and cholesteryl ester storage disease (CESD, the milder late-onset form). While these historical names remain common in literature, Lysosomal acid lipase deficiency is now the preferred clinical term to describe the spectrum of the disease caused by mutations in the LIPA gene.
The nomenclature for Lysosomal acid lipase deficiency reflects the evolution of medical understanding. Historically, physicians identified the condition based on the severity of symptoms rather than the underlying genetic cause. In the 1950s and 60s, the most severe, infantile-onset form was named Wolman disease after the physician who first described it. Simultaneously, a milder form presenting later in life was termed cholesteryl ester storage disease. As genetic testing advanced, researchers discovered that both conditions were caused by the same deficiency in the enzyme lysosomal acid lipase. Today, medical professionals use Lysosomal acid lipase deficiency as the umbrella term to encompass the entire clinical spectrum, though you will still see the older names used to denote specific severity levels.
In medical records and international databases, you may encounter various codes and abbreviations used to document Lysosomal acid lipase deficiency. These classifications are essential for insurance, clinical research, and global epidemiological tracking. Key designations include:
Because Lysosomal acid lipase deficiency presents as a continuum, clinicians often classify cases based on the age of onset and the rate of progression. Understanding these legacy terms is helpful when reviewing older medical literature or discussing your diagnosis with specialists:
Modern medicine prioritizes the underlying molecular cause of a disease over the historical names of individual cases. By using Lysosomal acid lipase deficiency, physicians can more accurately describe the pathophysiology—a lack of the enzyme that breaks down fats within the lysosome. This naming convention helps reduce confusion for patients and caregivers who may have previously received different labels for the same genetic condition. If you are communicating with your healthcare team, using the term Lysosomal acid lipase deficiency ensures clarity and aligns with current international diagnostic standards.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.